TO THE EDITOR
Real-time quantitative PCR (RQ-PCR) is used for diagnosis and detection of minimal residual disease (MRD) in bone marrow (BM) and peripheral blood (PB) of patients with acute lymphoblastic leukemia (ALL). Quantitative PCR analysis can be performed using tumour-specific DNA targets (eg Immunoglobin gene Rearrangements or IgR) but also using tumor specific RNA targets (eg fusion gene transcripts or FG). 1 Like IgR, the FG could be very informative in MRD follow-up, although IgR are the reflection of the cellular load whereas the FG are the reflection of the gene expression.
The FG RQ-PCR is limited by extraction, RT and PCR steps. In this last step, the study on DNA by PCR like IgR showed that amplification capacity applied to blood samples can be dramatically reduced or blocked by the presence of PCR inhibitors 2 like heme, anticoagulants such as EDTA and heparin but also immunoglobulin G. 3, 4 However, the problems observed in PCR on DNA samples are not necessarily shared by RT-PCR using RNA samples. Nevertheless, several cDNA samples may not give appropriate amplification in RQ-PCR analysis. For example, in our laboratory 13.6% of samples, of which 70% are of BM origin, are not amplifiable by RQ-PCR and therefore are defined as 'poor-quality' sample following EAC criteria (ie copy number for ABL control gene amplification o1000) established by a European network. 5 However, RNA degradation is not highlighted by Agilent 2100 Bioanalyzer analysis in the majority of these samples (not shown). In this context, it was decided to check if the failures of RQ-PCR in these samples were due to the presence of PCR-inhibitors. Thus, five 'poor-quality' samples according to EAC criteria (02/056, 02/135, 02/150, 02/156 and 02/157) and a 'good-quality' control sample (02/181) were used. For each one of these samples, dilution of cDNA, purification of cDNA on column and addition of an amplification facilitator, the bovine serum albumin (BSA), in the PCR buffer were performed. 3 PB and BM samples were obtained from patients with ALL during follow-up. From EDTA PB and heparinized BM samples, mononuclear cells (MNCs) were collected by centrifugation on a Ficoll-Hypaque density step (Eurobio, les Ulis, France). Cells were washed twice in RPMI-1640 medium (Invitrogen, Cergy, France). RNA extraction was performed using the TRIzol reagent (Invitrogen, Cergy, France) according to the manufacturer's recommendations. After extraction and isolation, RNA concentration was determined by measurement of the optical density at 260 nm (OD 260 ) and RNA quality was assessed using the Agilent 2100 Bioanalyzer (not shown). For RT and PCR steps, we applied the EAC protocol. 6 RQ-PCR was performed on the 7700 machine (ABI, Foster City, CA, USA). Standard curves for quantification were performed using plasmid (Ipsogen, France) dilutions ranging from 10 5 to 10 copies for TEL-AML1 or from 10 5 to 10 3 copies for ABL and allowed the determination of copy number (CN) for each transcript. To correct variations in RNA quantity, results of RQ-PCR amplifications were expressed as the ratio fusion transcript CN/control gene CN, also called normalized copy number (NCN). 5 The amplification of ABL control gene was tested by RQ-PCR in duplicate after cDNA dilution in water (Figure 1a) . With a 1/ 10 dilution of cDNA, the ABL CN of 'poor-quality' samples were comparable to that of the control sample for amplification (02/ 181) with the same dilution. However, the 1/10 dilution involves a loss of sensitivity of 1 log, which is not compatible with the follow-up of the MRD.
cDNA were purified on column and tested for ABL amplification (Figure 1b) . The purification of cDNA makes it possible to raise partial inhibition on four 'poor-quality' samples. However, the ABL CN never reaches the threshold value of 1000 copies. Moreover, the purification leads to a loss of material in particular for the control sample (02/181) as for sample 02/056 as assessed by the ABL RQ-PCR. Thus, extensive purification of cDNA adds time and expense for sample preparation and leads to the loss of target nucleic acid that prevents its use in MRD follow-up.
Addition of 0.04 or 0.2% BSA (Sigma-Aldrich, Poole, UK) in PCR is the most effective way to avoid inhibition ( Figure 1c ). BSA did not affect PCR efficiency and did not affect the ABL CN detected in the control sample (02/181) and in the calibrant plasmids. However, serial concentration of BSA highlighted that a final concentration of 0.4% in the RQ-PCR had a deleterious effect upon RQ-PCR efficiency (efficiency loss of a log approximately) (not shown). Moreover, the addition of BSA allows the amplification of ABL in five/five of the 'poor-quality' samples even in sample 02/157 which was not amplified in absence of BSA ( Figure 1c) . Importantly, the addition of 0.2% BSA in these samples is, among the three techniques we tested, the only one that allowed the detection of TEL-AML1 fusion gene transcript. Although being close to the detection threshold of RQ-PCR, the amplification of TEL-AML1 observed in sample 02/056 is reproducible one well on two in three separate experiments.
However, the comparison of results obtained on cDNA dilutions in the absence and in the presence of BSA indicates that there is no longer an inhibitory activity in the PCR (not shown). Thus, we tested the influence of BSA in the RT step for RQ-PCR analysis (not shown). The addition of 0.04 or 0.2% BSA in the RT at the moment of the addition of the enzyme did not modify positively the RQ-PCR results (not shown). Furthermore, the presence of 0.2% BSA in RT corresponds to a concentration of 0.02% BSA in PCR, which does not seem sufficient to prevent inhibition of PCR.
To confirm that the addition of BSA to RQ-PCR improves the transcript detection, a further 23 samples were analyzed in the absence or presence of BSA. On the one hand, results reported in Table 1 show that in amplifiable or 'good-quality' samples (ABL CN41000) addition of 0.04% BSA does not significantly modify ABL CN. On the other hand, the addition of 0.2% BSA decreases ABL CN in many cases. The majority of 'poor-quality' samples was sensitive to the addition of BSA (Table 2) , and in the presence of 0.04% BSA they can be considered as goodquality samples according to the EAC criteria allowing the clinical validation of the sample. For the remaining 'poorquality' samples that did not reach the threshold of 1000 copies for ABL amplification, several hypothesis can be raised: (i) an inhibition that is not overcome by the addition of BSA, (ii) the degradation of RNA, or (iii) a false evaluation of RNA quantity. However, the data obtained from the Agilent 2100 Bioanalyzer suggest that the integrity of RNAs was correct and, except for one of the seven samples tested, RNA quantity was accurate (not shown).
Thus, for these 'poor-quality' samples, it seems likely that reverse transcriptase is insensitive to the inhibitors present in RNA samples and that the addition of BSA in PCR is not sufficient to totally reverse inhibition.
Second, we also checked that addition of BSA had no effect on TEL-AML1 copy number in samples that present correct amplification of the ABL (CN 41000) (Figure 2b) . The TEL- Figure 1 ABL amplification: (a) In diluted cDNA. The cDNA of five nonamplified and one amplified (02/181) samples were diluted in water. RQ-PCR amplification of ABL control gene was carried out on the 7700 Taqman machine following the EAC protocol. The limit of amplifiability of samples is shown by dotted line (as defined by EAC network). 6 (b) In purified cDNA. The cDNA of five nonamplified and one amplified (02/181) samples were purified on column and amplification of ABL transcript was achieved following the EAC protocol. The limit of amplifiability of samples is shown by dotted line (as defined by EAC network). 6 (c) In cDNA with addition of BSA. RQ-PCR amplification of ABL control gene was in the presence of 0.04 and 0.2% of BSA. CN of ABL are shown for each sample. The limit of amplifiability of samples is shown by dotted line (as defined by EAC network). AML1 normalized copy numbers (NCN) are identical in the absence or in the presence of 0.04% BSA allowing quantification of FG (Figure 2c) . However, TEL-AML1 NCN were increased by the addition of 0.2% BSA secondarily to a reduction in the ABL CN (Figure 2 ). These data suggest that the beneficial role of BSA does not only summarize with a role 
In total, 12 different samples were analyzed for ABL and TEL-AML1 RQ-PCR. Samples were analyzed in the presence or absence of 0.04 or 0.2% BSA. a Quality (degradation) and quantity of RNAs were evaluated on 2100 Bioanalyzer (Agilent). ND, not determined; À, no amplification; +, positive nonquantifiable (CNo10).
of amplification facilitator. Taken together, these data show that only the addition of 0.04% BSA would allow a quantitative follow-up of the MRD. In the case of addition of 0.2% of BSA, there was a decrease in ABL CN (Figure 2a ) and an increase in TEL-AML1 CN (Figure 2b ) forbidding any accurate quantification. Actually, this effect was due to a variation of cycle threshold (C t ) value for the cDNA measurements with no modification of the plasmid standard curve (not shown).
We studied 12 'poor-quality' samples of patients who have a clinical and/or biological disease and possess TEL-AML1 FG. In 70% of the cases with or without ABL amplification, we recovered TEL-AML1 expression by the addition of 0.04 and/or 0.2% BSA. However, only one TEL-AML1-positive sample had an increase in ABL CN higher than 1000 by the addition of BSA in RQ-PCR, allowing quantification of the TEL-AML1 expression 6 (Table 3) . So, first, we have shown that the addition of BSA to TaqManbased RQ-PCR analysis improves amplification of 'poor-quality' samples. 6 Secondly, the addition of BSA is better than cDNA dilution or cDNA purification on column. Third, in certain cases, it allows improvement of relevant levels of FG like TEL-AML1.
In a clinical laboratory, each patient sample set for molecular MRD analysis is very valuable, so any improvement of RNA quality even in some samples is suitable to apply in practice.
Therefore, based on our data, this suggests that 0.04% BSA could be added systematically in ABL and TEL-AML1 RQ-PCR. This BSA concentration does not modify the RQ-PCR results of amplifiable samples and allows recovery to correct amplification of transcripts in some 'poor-quality' samples. Finally, a large prospective study is warranted to definitively assess the use of addition of 0.04% BSA in CG and FG RQ-PCR in a quantitative follow-up of the MRD. In chronic myeloid leukaemia (CML), the fusion gene BCR-ABL is created by the characteristic t(9;22) translocation. The fusion gene product is the p210 BCR-ABL protein, which has enhanced tyrosine kinase activity in comparison with wild-type ABL. The amino-acid sequences around the BCR-ABL fusion junction are novel to the immune system. Several groups have shown that peptides derived from the junction may elicit both CD8 þ cytotoxic T-cell (CTL) and CD4 þ proliferative T-cell responses in normal subjects and also elicit CTL responses in CML patients. It appears likely that BCR-ABL junctional peptides are endogenously presented in CML patients. CML cells may themselves present peptides derived from the BCR-ABL junction on the cell surface in association with HLA class I molecules. 1 Dendritic cells (DC) are potent antigen-presenting cells that have evolved to monitor the environment, detect pathogens and trigger T-cell responses. Several studies have established that DC in CML are derived from the leukaemic clone. DC from all 19 patients examined for BCR-ABL fusion by Fluorescent in situ hybridisation (FISH) in three studies were at least 73% FISH positive. [2] [3] [4] These patients had active disease at the time of study, mostly in first chronic phase. The DC used in each of these studies were derived from PB mononuclear cells, which in some cases were first selected for monocytes.
DC function may be abnormal in CML. CML cells have been shown to use a classic MHC class II antigen-processing pathway to present nonleukaemic antigens to CD4 þ T cells. 5 In comparison to normal DC, DC derived from CML patients demonstrate differences in cytoskeletal organisation and impaired migration, and a reduced capacity to capture and present nonleukaemic antigen. 6 CML-derived DC were less effective than normal DC in eliciting an allogeneic mixed lymphocyte reaction.
7 DC derived from CML patients have been shown to process and present endogenous BCR-ABL to CD4 þ T cells. 
